221 results about "Tryptamines" patented technology

Pharmaceutical compositions for the transmucosal delivery of N-N-dimethyltryptamine (DMT) acceptable salt or prodrug thereof in combination with a monoamine oxidase inhibitor to achieve desired bioavailability suitable for the treatment of neurological disorders.

A composition of a compound represented by FIGS. 1A-1E for use in treating a medical disorder. A method of changing neurotransmission, by administering a pharmaceutically effective amount of composition to a mammal of a compound represented by FIGS. 1A-1E and inducing psychoactive effects in the mammal. A method of treating a patient having adverse reactions to psychedelics or entactogens, by administering a pharmaceutically effective amount of composition to the patient of a compound represented by FIGS. 1A-1E and avoiding adverse effects present with psychedelics or entactogens.

This invention relates to pharmaceutically acceptable tryptamine analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.

The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.

The present disclosure provides engineered transaminase polypeptides for the production of amines, polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to prepare compounds useful in the production of active pharmaceutical agents.

The invention belongs to the technical field of iron ion detection, and particularly relates to a rapid detection method for ferric ions in water, which comprises the following steps: a fluorescent probe preparation step: taking trihydrate of copper nitrate and tryptamine, adding into a centrifuge tube in sequence, adding ultrapure water, performing ultrasonic dissolution, transferring into a high-pressure reaction kettle, and performing hydrothermal reaction to obtain a fluorescent probe; cooling to room temperature, centrifuging the obtained yellow green solution in a centrifugal machine, and filtering the supernate through a microfiltration membrane to obtain a copper-doped carbon quantum dot CuCDs stock solution, namely the fluorescent probe; analyzing and determining Fe < 3 + >: taking the diluent of the prepared CuCDs solution, adding the diluent into a centrifugal tube containing a Fe < 3 + > standard solution, uniformly mixing, carrying out fluorescent quantitative analysis and detection, and exploring the change rule of the fluorescence intensity ratio of CuCDs; according to the rapid detection method for Fe < 3 + > provided by the invention, the synthesized CuCDs have high sensitivity, can realize on-site rapid detection of Fe < 3 + > in a water medium, and shows a wide application prospect in the field of environmental monitoring.

A method of purifying 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is provided which comprises dissolving crude 5-MeO-DMT in a solvent at a temperature above room temperature, cooling the obtained solution to a temperature below room temperature to precipitate solid 5-MeO-DMT, separating the solid 5-MeO-DMT from the remaining solution and removing solvent from the crystalline 5-MeO-DMT. In the method, the solvent comprises one or more ethers and less than 5 wt % anti-solvent.

The invention discloses a method for synchronously, efficiently and directionally preparing indirubin and tryptanthrin by using a blue grass raw material, which comprises the following steps: pretreating blue grass to obtain blue grass powder or slurry; adding water into the blue grass powder or slurry, then adding a precursor substance, and carrying out ultrasonic or microwave treatment; according to different target products, static conversion or dynamic conversion can be carried out, or static conversion or dynamic conversion is carried out after microorganisms producing cellulase and oxygenase are inoculated, and the products are subjected to post-treatment such as drying and grinding. The method is simple to operate, high in processing efficiency, flexible in product scheme, low in production cost and suitable for large-scale production. The content of the indole alkaloid in the obtained material rich in the indole alkaloid is 1%-10%; the yield of indirubin reaches 5.64 mg / g, which is 21.7 times that of the traditional process; and the tryptanthrin yield reaches 7.68 mg / g, which is 10.8 times that of the traditional process.

To provide a compound useful for the treatment of mental disorders, such as a depressive condition including unipolar and bipolar depressive conditions, for example, but not limited to, depression, depression from generalized anxiety, major depression, treatment resistant depression, and postpartum depression.SOLUTION: The present invention provides a tryptamine prodrug compound represented by the following formula.SELECTED DRAWING: Figure 1

This invention belongs to the field of pharmaceutical chemistry, and specifically relates to a compound antifungal cream containing the traditional Chinese medicine ingredient tryptamine ketone and its application. The invention comprises the following components, with the following percentage content: stearic acid 10%~16%, glyceryl monostearate 3%~7%, liquid paraffin 5%~9%, tryptamine 0.1%~0.01%, terbinafine hydrochloride 0.00625%~0.000625%, glycerin 4%, triethanolamine 2%~6%, ethylparaben 0.5%, and the balance being purified water or distilled water. This invention is highly effective, low in toxicity, and exhibits low drug resistance.

The invention relates to a method for producing tryptamine. Disclosed herein are prokaryotic and eukaryotic microorganisms, including Escherichia coli and Saccharomyces cerevisiae, genetically altered to biosynthesize tryptamine and tryptamine derivatives. Microorganisms of the present disclosure may be engineered to comprise a plasmid and a stable gene integration containing genetic information sufficient to convert anthranilic acid or indole to tryptamine. Fermentative production of substituted tryptamine in the presence of a whole-cell biocatalyst can be used to economically and efficiently produce these compounds for therapeutic use.

The invention belongs to the technical field of organic compound preparation, and discloses a tryptanthrin compound as well as a preparation method and application thereof. The preparation method of the tryptanthrin compound disclosed by the invention comprises the step of enabling an indole-2, 3-diketone derivative, 2H-thieno [3, 2-D] [1, 3] oxazine-2, 4 (1H)-diketone, triethylamine and methylbenzene to react, so as to obtain the tryptanthrin compound. The obtained tryptanthrin compound is novel in structure, shows ulcerative colitis resisting activity and has the potential of being developed into ulcerative colitis resisting drugs.

The present application belongs to the technical field of pharmaceutical therapy, and particularly relates to an amide-substituted tryptophan ketone derivative, a preparation method and application thereof. The structural formula of the tryptophan ketone derivative is shown in formula (A) or formula (B). In the formula, n=1 or 2, and R is any one of dimethylamine group, diethylamine group, morpholine group, 1-methylpiperazine group, cyclopropylamine group and 4-hydroxypiperidyl group. The compound can selectively inhibit the activity of acetylcholinesterase, and has the potential to develop into a drug for treating Alzheimer's disease due to the abilities of self-aggregation and the like. 1‑42 ​

The invention belongs to the technical field of preparation of anti-inflammatory drugs, and particularly discloses a tryptanthrin derivative and a preparation method and application thereof.The structural formula of the tryptanthrin derivative is # imgabs0, R is one of R1, R2 and R3, and when R is R1, # imgabs1 # reacts with H-R1, Pd (PPh3) 2Cl, copper iodide, triethylamine and an organic solvent to prepare the tryptanthrin derivative; when R is R2, the catalyst is prepared by reacting # imgabs2 # with H-R2, Pd2 (dppf) Cl2, potassium acetate and methylbenzene; when R is R3, the PdCl (PPh3) 4 is prepared by reacting with H-R3, silver carbonate, PdCl (PPh3) 4 and acetonitrile. The tryptanthrin derivative disclosed by the invention has high biological activity and solubility and low toxicity, and has the potential of being developed into a medicine for treating ulcerative colitis.

The invention discloses a method for synthesizing novel alkaloid by enzyme catalysis of tryptamine and alpha-ketoamide substances, and the method comprises the following steps: reacting a compound shown as a formula (A) with a compound shown as a formula (B) in the presence of isoviscin synthetase to obtain alkaloid shown as a formula (C). The method is mild in condition, free of pollution and simple in process route.

The invention discloses an SERS (Surface Enhanced Raman Scattering) aptamer sensor based on a double-layer core-satellite magnetic gold nanostructure and a method for detecting biogenic amine in food by using the SERS aptamer sensor. The Fe3O4 (at) Au MNPs nanoparticles are combined with a nucleic acid aptamer, and a specific magnetic capture probe is obtained; the method comprises the following steps: mixing gold nanoparticle solutions with different particle sizes with 4-MBN, incubating to obtain a'biological silence zone 'SERS tag, and combining the'biological silence zone' SERS tag with pretreated sulfydryl modified c-DNA to obtain a specific SERS signal probe; and oscillating and incubating the specific SERS signal probe solution and the specific magnetic capture probe solution to obtain the SERS aptamer sensor based on the double-layer core-satellite magnetic gold nanostructure. According to the method, a'biological silence zone 'SERS label is combined with a magnetic induction technology, so that the problems of poor anti-interference performance and poor accuracy during detection of trace components in a complex matrix by SERS are solved, and high-efficiency detection of tryptamine in biogenic amine is realized.

The disclosure relates to a compound of formula (1):The disclosure also relates to a compound of formula (Ia):The disclosure relates to compositions comprising, consisting essentially of, or consisting of a compound of formula (I) or formula (Ia) and an excipient. The disclosure also relates to pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I) or formula (Ia) where the excipient is a pharmaceutically acceptable carrier. The disclosure further relates to therapeutic uses of compounds of formula (I) or formula (Ia).

The present invention relates to inhalable formulations, and kits and methods suitable for the preparation of such inhalable formulations. The inhalable formulations comprise a freebase of a deuterium-substituted dimethyltryptamine compound. The inhalable formulations also comprise a biocompatible excipient. Such formulations are suitable for inhalation and have uses in the treatment of psychiatric or neurological disorders. Deuterium-substituted dimethyltryptamine compounds may be metabolised more slowly than their protio analogues, allowing for a longer lasting therapeutic effect.

The invention features methods of treating depression in a subject in need thereof by administering to the subject a composition, and kits comprising 5-methoxy-N,N-dimethyltryptamine (5- MeO-DMT) in combination with a composition comprising one or more antidepressants, such as a selective serotonin reuptake inhibitor (SSRI), each in an amount that together are sufficient to treat depression in a patient in need thereof.

The application discloses a tryptamine detection method based on triple emission MOFs and a smart phone. A rare earth metal organic framework (AP-Eu) is used as a luminescent matrix, and a fluorescent guest molecule fluorescein-5-isothiocyanate (FITC) is post-modified to obtain a ratio fluorescent material with triple emission characteristics. Competitive absorption of ligands and tryptamine, pH response of FITC and hydrogen bonding are used to realize fluorescence signal regulation, and then high-sensitivity and high-selectivity fluorescence recognition of tryptamine is realized. The method is further applied to quantitative detection of tryptamine in beer samples, visualization detection of foam and on-site rapid detection assisted by a mobile phone APP. The application provides a safe and efficient tryptamine detection and fluorescence sensing method, and significantly improves detection accuracy and on-site applicability.

This disclosure relates to trimethyl[2-(5-methyl-1H-indol-3-yl)ethyl]azanium iodide (5-methyl-A / ,A / ,A / trimethyltryptammonium iodide or 5-Me-TMT iodide), crystalline 5-Me-TMT iodide, triethyl ┌2-(5-methyl-1H-indol-3-yl)ethyl┘azanium iodide (5-methyl-A / , / V, / V-triethyltryptammonium iodide or 5-Me-TET iodide), crystalline 5-Me-TET iodide, triethyl[2-(1-methyl-1H-indol-3-yl)ethyl]azanium iodide (1-methyl- / V, / V, / V-triethyltryptammonium iodide or 1-Me-TET iodide), crystalline 1-Me-TET iodide, [2-(5-methyl-1H-indol-3-yl)ethyl]tripropylazanium acetonitrile iodide (5-methyl- / V, / V, / V-tri-n-propyltryptammonium iodide acetonitrile or 5-Me-TPT iodide acetonitrile), crystalline 5-Me-TPT iodide acetonitrile, [2-(7-methyl-1H-indol-3-yl)ethyl]tripropylazanium iodide (7-methyl-A / ,A / ,A / -tri-n-propyltryptammonium iodide or 7-Me-TPT iodide), crystalline 7-Me-TPT iodide, and specific crystalline forms thereof, including crystalline form 1 of 5-Me-TMT iodide, crystalline form 1 of 5-Me-TET iodide, crystalline form 1 of 1-Me-TET iodide, crystalline form 1 of 5-Me-TPT iodide acetonitrile, and crystalline form 1 of 7-Me-TPT iodide, to compositions containing the same, and to methods of treatment using them.

The invention discloses a multi-copper oxidase mutant sourced from Psychrobacter sp. And capable of efficiently degrading biogenic amine and application of the multi-copper oxidase mutant. According to the multi-copper oxidase mutant, the 183rd site of an amino acid sequence shown in SEQ ID NO.1 is mutated into histidine from phenylalanine, the 221st site of the amino acid sequence shown in SEQ ID NO.1 is mutated into aspartic acid from asparagine, the 261st site of the amino acid sequence shown in SEQ ID NO.1 is mutated into glutamic acid from glutamine, and the 292nd site of the amino acid sequence shown in SEQ ID NO.2 is mutated into arginine from lysine. Compared with wild type multi-copper oxidase, the multi-copper oxidase mutant disclosed by the invention has a good degradation effect on tryptamine, phenylethylamine, putrescine, cadaverine, histamine, tyramine, spermidine and spermine, and the degradation rate on the spermidine and the spermine is increased to 100%, so that the multi-copper oxidase mutant has a good application prospect in food fermentation safety production.

The present disclosure relates to solid forms, such as salts, solvates, cocrystals and polymorphs, of Compound 1 as well as cocrystals of Compound 1 HO. Also disclosed are methods of preparing said solid forms, pharmaceutical compositions comprising the solid forms, and methods of treatment using said solid forms.

The present application relates to the technical field of pharmaceutical chemistry, and particularly relates to application of tryptophanone in prevention and treatment of plant bacteria and part of plant fungi. The present application discloses that natural product tryptophanone can effectively prevent and treat plant bacterial and part of plant fungal diseases. The application of tryptophanone as an agricultural bactericide in plant bacterial diseases has excellent inhibitory effect on rice bacterial leaf blight, rice bacterial leaf streak, citrus canker, cabbage black rot, tomato bacterial spot, kiwi canker, tobacco bacterial wilt, cucumber bacterial angular spot, potato bacterial wilt, soybean bacterial spot, tomato canker and the like. The tryptophanone also shows good inhibitory activity on plant pathogenic fungi such as grapevine Eutypa lata, tobacco alternaria alternata, eggplant verticillium wilt, pepper fusarium wilt, colletotrichum gloeosporioides, tea tree colletotrichum gloeosporioides and sorghum zylosporium.

The invention relates to an ethyl ester type fish oil preparation method based on sulfonic acid resin catalysis, and belongs to the technical field of deep processing of fish oil. Adding the fish oil, absolute ethyl alcohol and the modified sulfonic acid type resin into a reaction kettle for reaction, and standing to obtain an upper layer which is the ethyl ester type fish oil and a lower layer which is the glycerol and the sulfonic acid type resin; heating and condensing the upper-layer ethyl ester type fish oil to recover the absolute ethyl alcohol to obtain the ethyl ester type fish oil; separating and filtering glycerol and sulfonic acid resin on the lower layer, and packaging and selling the glycerol; eluting the filtered sulfonic acid type resin with absolute ethyl alcohol, drying under reduced pressure, and recycling; the modified sulfonic acid type resin is prepared from sodium type resin, food-grade polyethylene glycol, 5-hydroxytryptamine, food-grade gallic acid, food-grade L-cysteine, a food-grade ethanol-water mixed solution and a food-grade citric acid aqueous solution; the prepared ethyl ester type fish oil has the advantages of low acid value, high esterification rate, low free fatty acid content, good fish oil quality, advanced production process and high efficiency.

The present disclosure includes azetidine tryptamines and methods of treating psychiatric disorders with such compounds. Also provided are pharmaceutical compositions comprising azetidine tryptamine.

The present disclosure relates to compositions comprising N, N-dimethyltryptamine or a salt thereof and N, N-dimethyltryptamine or a salt thereof, pharmaceutical compositions comprising a combination of N, N-dimethyltryptamine or a salt thereof and N-acylethanolamine or a salt thereof with at least one pharmaceutically acceptable carrier and / or excipient and their use in a method of treating cerebral ischemia or hypoxia by administering the composition in a therapeutically effective amount to a subject in need thereof.